Acrivon Preclinical Data Showcase ACR-368 and ACR-2316 Synergies with PD-L1 and ADC Topo1
Acrivon will present three posters at AACR showing that ACR-368 synergized with anti-PD-L1 checkpoint inhibition and a Topo 1 ADC payload, while ACR-2316 combined with PD-L1 blockade produced complete tumor regression with durable immune memory. The preclinical data support frontline clinical development of ACR-368 and ACR-2316 in combinations with immune checkpoint inhibitors and ADC Topo 1 payload therapies.
1. Preclinical Synergy Findings
Acrivon’s preclinical studies demonstrated that ACR-368, a CHK1/2 inhibitor, exhibited strong synergistic anti-tumor activity when combined with anti-PD-L1 checkpoint inhibition and a Topo 1 ADC payload, while ACR-2316, a WEE1/PKMYT1 inhibitor, achieved complete tumor regression with durable immune memory in murine models.
2. Pipeline Assets and Trial Phases
ACR-368 is advancing in a registrational-intent Phase 2b trial for endometrial cancer after receiving FDA Fast Track designation, and ACR-2316 is in a Phase 1/2 study with established weekly dosing and early signs of clinical activity across solid tumors, including endometrial cancer, small-cell lung cancer and squamous non-small cell lung cancer.
3. Clinical Development Outlook
The preclinical data support development of frontline combination regimens pairing ACR-368 and ACR-2316 with immune checkpoint inhibitors and Topo 1 ADCs, guiding upcoming trial designs and offering potential new strategies for precision oncology therapeutics.